Search the Newsreel

Roivant Sciences (ROIV) Stock Rally Leans On Cash As Losses Persist

Roivant Sciences (ROIV) stock has rallied despite recent losses, driven by its strong cash position of nearly US$4.0 billion and a promising late-stage autoimmune pipeline. While the company recorded a net loss of US$189.84 million in Q1 2027, investors are focusing on pipeline milestones …

TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Announces Target Price $11.58

TD Cowen has reiterated its Buy rating for Artiva Biotherapeutics (ARTV.US) and set a target price of $11.58. This indicates the firm's continued confidence in the company's financial prospects and stock performance.

Wall Street Zen Upgrades Artiva Biotherapeutics (NASDAQ:ARTV) to Hold

Wall Street Zen has upgraded Artiva Biotherapeutics (NASDAQ:ARTV) from a "sell" to a "hold" rating, despite a broader analyst consensus of "Moderate Buy" with an average price target of $39.00. The company's stock has risen above its 50-day and 200-day moving averages and recently …

Innoviva (INVA) Stock Can Revenue Growth Offset A Sharp Profit Reversal

Innoviva (INVA) stock saw a 2.9% increase despite a significant Q2 2026 profit reversal, swinging from a profit of US$63.7 million to a loss of US$83.4 million. The company's revenue, however, grew by 19% to US$119.6 million, driven by its Specialty Therapeutics portfolio and …

Notícias das Ações da LivaNova PLC (LIVN)

Univastu India consolidated net profit rises 281.61% in the June 2026 quarter

LivaNova PLC (LIVN) Stock News Today

Activate Energy Acquisition Ord Shs Class A (AEAQ) Stock News Today

Artiva Biotherapeutics (NASDAQ:ARTV) Announces Quarterly Earnings Results

Artiva Biotherapeutics (NASDAQ:ARTV) reported a quarterly loss of $0.63 per share, beating analyst estimates. The stock, currently trading around $11.58, has seen significant insider buying totaling nearly $107.7 million over the past 90 days. Analysts maintain a "Moderate Buy" consensus with a target price …

ARTIVA BIOTHERAPEUTICS INC: QTRLY EPS $-0.63

Artiva Biotherapeutics Inc. reported quarterly earnings per share (EPS) of $-0.63. This financial update, originally sourced from Reuters, provides key information for investors and market watchers interested in the company's recent performance. The article focuses solely on this financial figure without further elaborating on …

How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors

Innoviva, Inc. reported mixed Q2 2026 results with increased revenue but a swing from net income to a significant net loss, while also completing a substantial share repurchase. This financial performance and capital allocation strategy may prompt investors to re-evaluate the company's investment narrative, …

Innoviva Inc (INVA) Stock News Today

This article provides current stock information for Innoviva Inc (INVA), including its stock price, market cap, and P/E TTM. It indicates that further news, earnings reports, analyst ratings, and key developments are anticipated to be published soon on the platform. The page primarily serves …

Shiva Mills Ltd is Rated Strong Sell

Can Clarivate’s (CLVT) Agentic AI Push Deepen Its Moat Or Signal A Riskier Shift?

Clarivate Plc recently expanded agentic AI capabilities across its Cortellis portfolio, embedding natural language and multi‑agent tools into life sciences R&D, safety and competitive intelligence workflows to cut manual effort and speed evidence-based decisions. This move effectively turns Cortellis into a more embedded decision …

Roivant Sciences Ltd (ROIV) Stock News Today

iValue Infosolutions to host investor meet at Emkay Confluence 2026

Ivanhoe Mines Downplays Impact of Longstanding DRC Concentrate Export Ban

Inventiva SA (IVA) Stock News Today

Ivanhoe Electric (IE) Reports Q2 Loss, Lags Revenue Estimates

Ivanhoe Electric Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Ivanhoe Mines Ltd. (IYAA.F) Stock Price, News, Quote & History

Artiva Biotherapeutics reports Q2 2026 net loss $25.0M, cash $349.4M to fund operations into 2029

Artiva Biotherapeutics reported a net loss of $25.0 million for Q2 2026 and holds $349.4 million in cash, cash equivalents, and investments, projected to fund operations into 2029. The company highlighted clinical progress for its AlloNK program, including FDA's RMAT designation for AlloNK plus …

Renaissance Technologies LLC Makes New $4.25 Million Investment in Ivanhoe Electric Inc. $IE

SBCL: Q1 FY27 revenue up 33% YoY, PAT up 44% YoY, with strong export and margin gains

Knowledge graphs: Turning fragmented biomedical data into connected, actionable insight

This article discusses how knowledge graphs address the challenge of fragmented biomedical data, transforming it into actionable insights. It highlights that the problem is not data abundance but usability, with knowledge graphs connecting disparate data points into a unified framework. The piece also explains …

Roivant Sciences Ltd. 2026: Revenue $1.44M, EPS ($0.26) — 10-Q Summary

Roivant Sciences Ltd. (ROIV) reported its 2026 quarterly results, showing revenue of $1.44 million and a diluted loss per share of ($0.26). This represents a decrease in revenue and an improvement in diluted EPS compared to the prior-year quarter. The company also highlighted pipeline …

Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $39.73, Implies 15% Upside

Roivant Sciences Ltd. (ROIV) has seen its average 12-month price target raised from $38.91 to $39.73 by 11 analysts, with forecasts ranging from $34 to $50 per share. This new target implies a potential upside of approximately 15% based on the August 5th closing …

Owens Corning (OC) Is Up 8.5% After Q2 Earnings Beat, Buybacks And CFO Transition – What's Changed

In early August 2026, Owens Corning reported second-quarter 2026 results showing broadly flat sales at US$2,756 million year on year, but a decline in net income to US$226 million and lower earnings per share compared with the prior-year quarter. Alongside these results, the company …

Shivalik Bimetal Controls Ltd. Share Price at 52-Week High

CD Private Equity Fund II (ASX:CD2) Declines as Financials Sector Comes Under Pressure

Shiva Texyarn Q1FY27 net profit falls 24% to ₹1.72 crore

Clarivate Plc (CLVT) Stock Forecasts

Clarivate Plc (CLVT) is a data, information, and software workflow solutions company, primarily serving academia, government, law, life sciences, and healthcare sectors. An analyst report from Morningstar on August 6, 2026, suggests that Clarivate is in the early stages of a multiyear turnaround. The …

Trivago N.V. ADS (NASDAQ:TRVG) Price Target Raised to $5.50

Susquehanna has increased its price target for Trivago N.V. ADS (NASDAQ:TRVG) from $3.25 to $5.50, while maintaining a "neutral" rating, suggesting a potential upside of 6.18%. Despite this, analyst sentiment remains cautious, with a consensus rating of "Reduce" and an average price target of …

Shiva Mills reports standalone net profit of Rs 2.83 crore in the June 2026 quarter

Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial

Vivani Medical announced the completion of enrollment and initial dosing for all 20 participants in its Phase 1 SLIM-1 trial. The trial is evaluating NPM-139, a long-acting semaglutide implant, for chronic weight management, focusing on its safety and tolerability.

Vivakor closes $12 million convertible note private placement

Vivakor Inc. (NASDAQ:VIVK) has successfully closed a $12 million convertible note private placement, securing $15 million in principal amount including the original issuance discount. The funds will be used to reduce debt, support working capital, advance its Houston Remediation Processing Center, and further its …